Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty

Gefitinib

Gefitinib
Gefitinib (ZD1839) is an EGFR first-generation inhibitor with oral activity that inhibits the EGFR 19 Del and L858R mutations. Gefitinib has antitumor activity and is used for the treatment of EGFR-mutated non-small-cell lung cancers. Gefitinib administration RESULTS in the development of the EGFR C797S resistance mutation.
Catalog No. T1181Cas No. 184475-35-2
Select Batch
Purity:100%
Contact us for more batch information

Resource Download

Gefitinib

Catalog No. T1181Cas No. 184475-35-2

Gefitinib (ZD1839) is an EGFR first-generation inhibitor with oral activity that inhibits the EGFR 19 Del and L858R mutations. Gefitinib has antitumor activity and is used for the treatment of EGFR-mutated non-small-cell lung cancers. Gefitinib administration RESULTS in the development of the EGFR C797S resistance mutation.
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Pack SizePriceAvailabilityQuantity
100 mg$50In Stock
500 mg$57In Stock
1 g$74In Stock
5 g$148In Stock
1 mL x 10 mM (in DMSO)$50In Stock
Bulk & Custom
Add to Cart

Related Compound Libraries of "Gefitinib"

Product Introduction

Bioactivity
Description
Gefitinib (ZD1839) is an EGFR first-generation inhibitor with oral activity that inhibits the EGFR 19 Del and L858R mutations. Gefitinib has antitumor activity and is used for the treatment of EGFR-mutated non-small-cell lung cancers. Gefitinib administration RESULTS in the development of the EGFR C797S resistance mutation.
Targets&IC50
Tyr1173:37 nM (NR6wtEGFR cells), Tyr1173:26 nM (NR6W cells), Tyr992:37 nM (NR6wtEGFR cells) , Tyr992:57 nM (NR6W cells)
In vitro
METHODS: Twenty-three tumor cells were treated with Gefitinib for 72 h, and cell viability was measured by MTT.
RESULTS: Only the PC9 cell line had an IC50 <1 μmol/L (highly sensitive), 14 cell lines had an IC50 >10 μmol/L (resistant), and the remaining 8 cell lines had an IC50 of 1-10 μmol/L (moderately sensitive). [1]
METHODS: Tumor cells HT29, KB, Du145 and A549 were treated with Gefitinib (0.032-50 μM) for 2 h. EGF (0.1 μg/mL) was added five minutes prior to cell lysis, and the expression levels of target proteins were detected using Western Blot.
RESULTS: Gefitinib produced a dose-dependent inhibition of EGFR autophosphorylation in all tumor cell lines. [2]
In vivo
METHODS: To detect anti-tumor activity in vivo, Gefitinib (3.125-200 mg/kg in 0.5% polysorbate 80) was administered orally to nude mice harboring tumors A431, Du145, or A549 once a day for seven to fifteen days.
RESULTS: Gefitinib inhibited the growth of A431, Du145 or A549 tumors in a dose-dependent manner. [2]
METHODS: To assay antitumor activity in vivo, Gefitinib (40 mg/kg once daily) or Gefitinib (200 mg/kg every five days) was administered by gavage for two weeks to athymic nude mice harboring the human lung cancer tumor H3255.
RESULTS: Weekly treatment showed better inhibition than daily treatment. Compared with the daily dosing regimen, the weekly dosing regimen showed stronger inhibition of p-EGFR, p-ERK, and p-AKT. [3]
Cell Research
The human NSCLC H1299, H1975, A549, H460, GLC82, H460, and CALU-3 cell lines were provided by the American Type Culture Collection and maintained in RPMI-1640 supplemented with 10% FBS in a humidified atmosphere with 5% CO2. CALU-3 GEF-R is a cell line obtained in vitro as previously described. Briefly, over a period of 12 months, human CALU-3 lung adenocarcinoma cells were continuously exposed to increasing concentrations of gefitinib. The starting dose was the dose causing the inhibition of 50% of cancer cell growth (IC50; gefitinib, 1 μmol/L). The drug dose was progressively increased to 15 μmol/L in approximately 2 months, to 20 μmol/L after other 2 months, to 25 μmol/L after additional 2 months, and, finally, to 30 μmol/L for a total of 12 months. The established resistant cancer cell lines were then maintained in continuous culture with the maximally achieved dose of each TKI that allowed cellular proliferation (30 μmol/L for each drug) [2].
Animal Research
Four- to 6-week old female balb/c athymic (nu+/nu+) mice were purchased from Charles River Laboratories. Mice were acclimatized for 1 week before being injected with cancer cells and injected subcutaneously with 107 H1299 and CALU-3 GEF-R cells that had been resuspended in 200 μL of Matrigel. When established tumors of approximately 75 mm3 in diameter were detected, mice were left untreated or treated with oral administrations of metformin (200 mg/mL metformin diluted in drinking water and present throughout the experiment), gefitinib (150 mg/kg daily orally by gavage), or both for the indicated time periods. Each treatment group consisted of 10 mice. Tumor volume was measured using the formula π/6 × larger diameter × (smaller diameter)2. Tumor tissues were collected from the xenografts and analyzed by Western blotting for the expression and activation of EGFR, AMPK, mitogen-activated protein kinase (MAPK), and S6 [2].
AliasZD1839
Chemical Properties
Molecular Weight446.9
FormulaC22H24ClFN4O3
Cas No.184475-35-2
Storage & Solubility Information
StoragePowder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.
Solubility Information
DMSO: 18.33 mg/mL (41.02 mM)
Ethanol: 4.5 mg/mL (10 mM)
10% DMSO+40% PEG300+5% Tween 80+45% Saline: 4.47 mg/mL (10 mM), Working solution is recommended to be prepared and used immediately.
Solution Preparation Table
Ethanol/10% DMSO+40% PEG300+5% Tween 80+45% Saline/DMSO
1mg5mg10mg50mg
1 mM2.2376 mL11.1882 mL22.3764 mL111.8819 mL
5 mM0.4475 mL2.2376 mL4.4753 mL22.3764 mL
10 mM0.2238 mL1.1188 mL2.2376 mL11.1882 mL

Calculator

  • Molarity Calculator
  • Dilution Calculator
  • Reconstitution Calculator
  • Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
TargetMol | Animal experimentsFor example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . TargetMol | Animal experiments A total of 10 animals were administered, and the formula you used is 5% TargetMol | reagent DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。
Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSOTargetMol | reagent (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
Preparation method for in vivo formula: Take 50 μL DMSOTargetMol | reagent main solution, add 300 μLPEG300TargetMol | reagent mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2OTargetMol | reagent mix well and clarify
For Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
1 Enter information below:
mg/kg
g
μL
2 Enter the in vivo formulation:
% DMSO
%
%Tween 80
%ddH2O

Dose Conversion

You can also refer to dose conversion for different animals. More

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc

Keywords

Related Tags: buy Gefitinib | purchase Gefitinib | Gefitinib cost | order Gefitinib | Gefitinib chemical structure | Gefitinib in vivo | Gefitinib in vitro | Gefitinib formula | Gefitinib molecular weight